Challenges and Solutions in the Intranasal Corticosteroids Market By 2023 to 2033 from Sanket Badgujar's blog

The global intranasal corticosteroids market demand is predicted to expand at a CAGR of 5.0% during the forecasted period, according to data from Future Market Insights. From US$ 6.8 billion in 2023 to US$ 11.2 billion in 2033, the market value is anticipated to rise. The market for intranasal corticosteroids was estimated to be worth US$ 6.5 billion at the end of 2022 and is expected to expand by 4.8% year over year in 2023.

The immunotherapy treatment segment is experiencing rapid growth in the market due to its high efficacy, despite the issue of high prices associated with this treatment. Manufacturers are actively focusing on developing targeted immunotherapy treatments to offset the decline in revenue caused by patent expiry.

Request A Sample Copy Of This Research Report! https://www.futuremarketinsights.com/reports/sample/rep-gb-9329

Companies are also strategically planning their product portfolio to align with the patent life cycle, filing for new patents based on dosage and prescription to maintain their market position. This is attributed to the increasing number of prescription drugs being switched to over-the-counter availability. Notably, the growing trend of self-medication in the United States presents a significant growth opportunity for manufacturers of allergic rhinitis treatment products.

In general, it is expected that the intranasal corticosteroid market will continue to experience growth in the coming years. This market offers customers an affordable and convenient option to enhance their smile.

Key Takeaways from Market Study:

• Fluticasone Propionate lead the global market with 3% value share in 2022, owed to its effectiveness in reducing airway inflammation compared to other drugs.
• The corticosteroids used for treatment of allergic rhinitis especially seasonal allergies top the sale around globe with value share of around 1% in 2022. This is due to the high amount of pollens release from plant, fungi, seeds during seasonal change.
• Retail Pharmacies accounted for dominant market share for distribution of intranasal corticosteroids in 2022 with 7% value share. This can be attributed to the fact that retail pharmacies have a strong presence with numerous conveniently located branches in various neighborhood and communities allowing for easy accessibility and availability of drugs.
• Intranasal sprays dominated globally with market share of around 3% in 2022, owed to easy administration of drugs into the nose.
• In North America, the United States exhibited rising trend of intranasal corticosteroid usage due to over the counter self-medication purchase for treatment of rhinitis. U.S. market held a value share of around 3% in 2022 globally.

“Intranasal corticosteroids is a thriving market driven by rising allergic rhinitis cases, self-medication trends, making it profitable sector to venture by entrepreneurs ” says an analyst of Future Market Insights.

Market Competition:

Pharma industries are involved in research and development to make the corticosteroid delivery fast and with higher efficiency. The medications are also made cheaper with respect to pre-existing drug to reduce competition

• In September 2022, Ryaltris has been approved by the US Food and Drug Administration, and it provides a wide variety of therapy options for children to the elderly, with the added bonus of having an onset of action of 15 minutes for nasal symptoms.

Key Companies Profiled:

• Merck & co.
• GlaxoSmithKline
• AstraZeneca
• Sanofi
• Perrigo Co.
• Teva Pharmaceutical Industries
• Glenmark Pharmaceuticals
• Mylan
• Novartis
• Pfizer
• Pharmascience

Key Market Segments Covered in the Intranasal Corticosteroids Industry Research:

By Drug:

• Fluticasone Propionate
• Budesonide
• Beclomethasone Dipropionate
• Mometasone Furoate
• Triamcinolone Acetonide
• Ciclesonide
• Flunisolide
• Tixocortol

By Indication:

• Allergic Rhinitis (AR)
• Seasonal AR
• Perennial AR
• Non-Allergic Rhinitis (NAR)
• Infectious NAR
• Vasomotor NAR
• Atrophic NAR

By Dosage Form:

• Intranasal Drops
• Intranasal Sprays

By Distribution Channel:

• Hospitals Pharmacies
• Drug Stores
• Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East and Africa